Enrolling pregnant women: issues in clinical research.

BACKGROUND Despite the fact that many pregnant women are affected by a range of serious health conditions and take medications for these conditions, there is widespread reticence to include them in clinical intervention research. Hence, their clinical care is typically not informed by evidence derived from pregnant populations. METHOD In October 2010, the National Institutes of Health Office of Research on Women's Health convened a workshop to address ethical, regulatory, and scientific issues raised by the enrollment of pregnant women in clinical research. This report summarizes three areas that emerged from that meeting as important next steps to be taken to promote ethically responsible and scientifically sound research during pregnancy. FINDINGS The three areas are: 1) Reclassify pregnant women from their current status in regulations as a "vulnerable" population to a scientifically "complex" population and change the presumption of exclusion to one of inclusion; 2) examine the institutional review boards' (IRB) gatekeeper role in interpreting regulations governing pregnancy research and identify steps to facilitate IRB approval of ethically informed pregnancy research; and 3) develop a pregnancy-focused research agenda that addresses pressing clinical needs, identifies opportunities to gather information from existing resources and studies, and encourages important new research areas. CONCLUSION Research is needed to address the therapeutic needs of pregnant women and to study pregnancy as it may shed light on a pregnant woman's later health and the health of her child.

[1]  C. Grady,et al.  Clinical research enrolling pregnant women: a workshop summary. , 2011, Journal of women's health.

[2]  A. Lyerly,et al.  The Second Wave: Toward Responsible Inclusion of Pregnant Women in Research , 2009, International journal of feminist approaches to bioethics.

[3]  S. Wood,et al.  Policy implications of a new National Institutes of Health Agenda for Women's Health Research, 2010-2020. , 2011, Women's health issues : official publication of the Jacobs Institute of Women's Health.

[4]  P. Vicini,et al.  Amoxicillin Pharmacokinetics in Pregnant Women: Modeling and Simulations of Dosage Strategies , 2007, Clinical pharmacology and therapeutics.

[5]  J. Harding,et al.  The developmental origins of adult disease (Barker) hypothesis , 2006, The Australian & New Zealand journal of obstetrics & gynaecology.

[6]  Seema K. Shah,et al.  How do institutional review boards apply the federal risk and benefit standards for pediatric research? , 2004, JAMA.

[7]  Robert L Davis,et al.  Prescription drug use in pregnancy. , 2004, American journal of obstetrics and gynecology.

[8]  R. Macklin Enrolling pregnant women in biomedical research , 2010, The Lancet.

[9]  A. Lyerly,et al.  Reframing the Framework: Toward Fair Inclusion of Pregnant Women as Participants in Research , 2011, The American journal of bioethics : AJOB.

[10]  C. Feudtner,et al.  Variation in Standards of Research Compensation and Child Assent Practices: A Comparison of 69 Institutional Review Board–Approved Informed Permission and Assent Forms for 3 Multicenter Pediatric Clinical Trials , 2006, Pediatrics.

[11]  Sielert Me,et al.  A Workshop Report , 1968 .

[12]  N. Press,et al.  Feeding the fetus: on interrogating the notion of maternal-fetal conflict. , 1997, Feminist studies : FS.

[13]  M. Schull,et al.  Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study , 2005, The Lancet.

[14]  B. B. Little,et al.  Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. , 1999, Obstetrics and gynecology.

[15]  S. F. Goldkind,et al.  Enrolling pregnant women in research--lessons from the H1N1 influenza pandemic. , 2010, The New England journal of medicine.

[16]  Michael K. Skinner,et al.  Transgenerational epigenetic imprints on mate preference , 2007, Proceedings of the National Academy of Sciences.

[17]  Seema K. Shah,et al.  Institutional review board practices regarding assent in pediatric research. , 2004, Pediatrics.

[18]  J. Coverdale,et al.  A comprehensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women. , 2005, American journal of obstetrics and gynecology.

[19]  Michael K. Skinner,et al.  Epigenetic Transgenerational Actions of Endocrine Disruptors and Male Fertility , 2005, Science.

[20]  C. Chambers,et al.  Drug Safety in Pregnant Women and Their Babies: Ignorance Not Bliss , 2008, Clinical pharmacology and therapeutics.